Genzyme buys Pharming Pompe assets

GENZ will acquire from Pharming (EuroNext:PHAR; NASD-EU:PHAR) all remaining assets related to the diagnosis and treatment of Pompe disease, including IP and licenses, preclinical and clinical data. GENZ also will acquire Pharming N.V., PHAR's Belgium business and will release PHAR from capital claims to joint ventures related to the development of a Pompe disease treatment. ...